Gerstmann-Straussler-Scheinker Disease, I, Extending the Clinical Spectrum
Neurol 39:1446-1452, Farlow,M.R.,et al, 1989
Nervous System Toxicity of Chemo Agents
Young, DF, in Vinken PJ, Bruyn GW, Handbook of Clin Neurol, North-Holland Publ Co, Amster, Vol 39, 1, 80, p 104, 1980
Gait Analysis in Neurologic Disorders, Methodology, Applications and Clinical Considerations
Neurol 105:e214154, Ali,F.,et al, 2025
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Molecular Basis of the Neurodegenerative Disorders
NEJM 340:1970-1980, Martin,J.B., 1999
Clinical Usefulness of Magnetic Resonance Imaging in Multiple System Atrophy
JNNP 65:65-71, Schrag,A.,et al, 1998
Familial Idiopathic Brain Calcification with Autosomal Dominant Inheritance
Neurol 48:645-649, Kobari,M.,et al, 1997
Clinicopathological Study of 35 Cases of Multiple System Atrophy
JNNP 58:160-166, Wenning,G.K.,et al, 1995
The Motor Disorder of Multiple System Atrophy
JNNP 56:1239-1242, Quinn,N.P.&Marsden,C.D., 1993
Wilson's Disease:The Problem of Delayed Diagnosis
JNNP 55:692-696, Walshe,J.M.&Yealland,M., 1992
Presynaptic Parkinsonism in Olivopontocerebellar Atrophy:Clinical, pathological, and Neurochemical Evidence
Ann Neurol 30:425-428, Pascual,J.,et al, 1991
Neurological and Neuropsychiatric Spectrum of Wilson's Disease:A Prospective Study of 45 Cases
J Neurol 238:281-287, Oder,W.,et al, 1991
Movement Disorders in Alcoholism:A Review
Neurol 40:741-746, Neiman,J.,et al, 1990
Creutzfeldt-Jakob Disease without Periodic Sharp Wave Complexes:A Clinical, EEG, and Path Study
Neurol 38:1056-1060, Zochodne,D.W.,et al, 1988
Azorean Disease of the Nervous System
NEJM 296:1505, Romanul,F.C.A.,et al, 1977
Normocalcemic Tetany
Neurol 26:825, Isgreen,W.P., 1976
Vitamin B6 Deficiency Presenting with New-Onset Epilepsy and Status Epilepticus in a Patient with Parkinson Disease
Neurol 94:e2605-e2607, Modica, J.S.,et al, 2020
The Laser Shoes
Neurol 90:e164-e171, Barthel, C.,et al, 2018
Distinguishing Neuroimaging Features in Patients Presenting with Visual Hallucinations
AJNR 37:774-781, Winton-Brown, T.T.,et al, 2016
Gait Freezing and Speech Disturbance in Parkinsons Disease
Neurol Sci 35:357-363, Park,H.K.,et al, 2014
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis
Arch Neurol 68:899-904, Weintraub, D.,et al, 2011
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Arch Neurol 67:58-63, Rabinak,C. &Nirenberg,M., 2010
A Meta-Regression of the Long-Term Effects of Deep Brain Stimulation on Balance and Gait in PD
Neurol 75:1292-1299, St. George,R.J.,et al, 2010
What Predicts Mortality in Parkinson Disease? A Prospective Population-Based Long-Term Study
Neurol 75:1270-1276, Forsaa,E.B.,et al, 2010
Neuroimaging of Bilateral Caudate Infarction Manifesting as Parkinsonian Gait Disorder
Conn Med 71:149-150, Finelli,P.F., et al, 2007
Improvement of Gait by Chronic, High Doses of Methylphenidate in Patients with Advanced Parkinsons Disease
JNNP 78:470-475, Devos,D.,et al, 2007
Quetiapine for Agitation or Psychosis in Patients with Dementia and Parkinsonism
Neurol 68:1356-1363, Kurlan,R.,et al, 2007
Benign Tremulous Parkinsonism
Arch Neurol 63:354-357,321, Josephs,K.A.,et al, 2006
Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)
Neurol 66:996-1002, Miyasaki,J.M.,et al, 2006
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Pract Neurology 4:50-55, Razvi,S.S.M. &Muir,K.W., 2004
Does This Patient Have Parkinson Disease?
JAMA 289:347-353, Rao,G.,et al, 2003
Ten Most Commonly Asked Questions About the Psychiatric Aspects of Parkinson's Disease
The Neurologist 9:50-56, Reich,S.G. & Marsh,L., 2003
Treatments of Parkinson Disease
Arch Neurol 60:1680-1684, Shults,C.W., 2003
Effects of Bilateral Subthalamic Nucleus Stimulation on Parkinsonian Gait
Neurol 57:144-146, Stolze,H.,et al, 2001
The Nonmotor Problems of Parkinson's Disease
The Neurologist 6:18-27, Friedman,J.H.&Fernandez,H.H., 2000
Quetiapine for L-Dopa-Induced Psychosis in PD
Neurol 54:1538, Weiner,W.J.,et al, 2000
Treatment of Drug-Induced Psychosis with Quetiapine and Clozapine in Parkinson's Disease
Neurol 55:1753-1754, Dewey,R.B.Jr. & O'Suilleabhain,P.E., 2000
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
NEJM 340:757-763,801, The Parkinson Study Group, 1999
Clinical Correlates of Vascular Parkinsonism
Arch Neurol 56:98-102, Winikates,J.&Jancovic,J., 1999
Prevalence and Clinical Correlates of Psychotic Symptoms in parkinson Disease
Arch Neurol 56:595-601, Aarsland,D.,et al, 1999
Transderm-induced Psychosis in Parkinson's Disease
Neurol 53:433-434, Minagar,A.,et al, 1999
Recent Advances, Neurology
BMJ 319:362-366, Larner,A.J.&Farmer,S.F., 1999
An Algorithm (Decision Tree) for the Management of Parkinson's Disease:Trtm Guidelines
Neurol 50:S1-S57, Olanow,C.W.&Koller,W.C., 1998
Clinical Presentation and Pharmacological Therapy in Corticobasal Degeneration
Arch Neurol 55:957-961, Kompoliti,K.,et al, 1998
Acute Delirium After Withdrawal of Amantadine in Parkinson's Disease
Neurol 50:1456-1458, Factor,S.A.,et al, 1998
Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 50:1195-1196, Wolters,E.C.,et al, 1998